A 2013 study reported that FadA facilitates CRC progression by modulating E-cadherin/β-catenin signaling.158 Later in 2019, FadA was shown to work in concert with Annexin A1 to activate β‐catenin in CRC cells, thus accelerating cancer growth.110 An excreted amyloid-like form of FadA was also shown to promote CRC progression by serving as a scaffold for biofilm formation and host cell adherence.159 Additionally, this study found that production of FadA increases acid tolerance, which may be an important mechanism to facilitate GI translocation. Here, ANXA1 is linked to colorectal carcinoma.